Research graph
References from Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation. Local targets link to admitted publications; unresolved targets remain external evidence.
Multiple sclerosis: geoepidemiology, genetics and the environment
10.1016/j.autrev.2009.11.010 · 2010 · External reference
Multiple sclerosis: risk factors, prodromes, and potential causal pathways
10.1016/s1474-4422(10)70094-6 · 2010 · External reference
10.1586/14737175.2013.865866
10.1586/14737175.2013.865866 · External reference
10.1191/135245899678846032
10.1191/135245899678846032 · External reference
Defining the clinical course of multiple sclerosis
10.1212/wnl.0000000000000560 · 2014 · External reference
Multiple sclerosis
2018 · External reference
Primary progressive multiple sclerosis: current and future treatment options
10.2165/00023210-200519050-00001 · 2005 · External reference
The role of advanced magnetic resonance imaging techniques in primary progressive MS
10.1007/s00415-011-6195-6 · 2012 · External reference
10.1109/bibm52615.2021.9669331
10.1109/bibm52615.2021.9669331 · External reference
10.1038/s41573-019-0035-2
10.1038/s41573-019-0035-2 · External reference
The mechanism of action of glatiramer acetate in multiple sclerosis and beyond
10.1016/j.autrev.2012.09.005 · 2013 · External reference
Progress in the application of drugs for the treatment of multiple sclerosis
2021 · External reference
10.1016/s0140-6736(21)00244-0
10.1016/s0140-6736(21)00244-0 · External reference
10.1080/14737175.2019.1561284
10.1080/14737175.2019.1561284 · External reference
Treatment of multiple sclerosis with Anti-CD20 antibodies
10.1016/j.clim.2011.04.005 · 2012 · External reference
10.1177/1756285615601933
10.1177/1756285615601933 · External reference
Cladribine: mechanisms and mysteries in multiple sclerosis
10.1136/jnnp-2017-317411 · 2018 · External reference
Short term efficacy and safety outcomes after switching from Anti-CD20 DMTs to Cladribine in a real-world setting (5389)
10.1212/wnl.94.15_supplement.5389 · 2020 · External reference
10.1097/wnf.0b013e318204cd90
10.1097/wnf.0b013e318204cd90 · External reference
Computational modeling of brain pathologies: the case of multiple sclerosis
2018 · External reference
The potential of computational modeling to predict disease course and treatment response in patients with relapsing multiple sclerosis
10.3390/cells9030586 · 2020 · External reference
The potential of computational modeling to predict disease course and treatment response in patients with relapsing multiple sclerosis
10.3390/cells9030586 · 2020 · External reference
10.1056/nejmoa1601277
10.1056/nejmoa1601277 · External reference
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study
10.1177/1352458517727603 · 2018 · External reference
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
10.1056/nejmoa0902533 · 2010 · External reference
A multi-step and multi-scale bioinformatic protocol to investigate potential SARS-CoV-2 vaccine targets
10.1093/bib/bbab403 · 2022 · External reference
Predicting the artificial immunity induced by RUTI® vaccine against tuberculosis using universal immune system simulator (UISS)
10.1186/s12859-019-3045-5 · 2019 · External reference
In silico design of recombinant multi-epitope vaccine against influenza A virus
2021 · External reference
10.1371/journal.pone.0154556
10.1371/journal.pone.0154556 · External reference
Multiple sclerosis immunology: the healthy immune system vs the MS immune system
10.1212/wnl.0b013e3181c97c8f · 2010 · External reference
10.1038/s41591-022-01823-1
10.1038/s41591-022-01823-1 · External reference
10.1146/annurev.immunol.23.021704.115707
10.1146/annurev.immunol.23.021704.115707 · External reference
Cladribine (2-chlorodeoxyadenosine)
10.1016/0140-6736(92)92826-2 · 1992 · External reference
Immunomodulatory effects associated with cladribine treatment
10.3390/cells10123488 · 2021 · External reference
Integrated lymphopenia analysis in younger and older patients with multiple sclerosis treated with cladribine tablets
10.3389/fimmu.2021.763433 · 2021 · External reference
Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis
10.1016/j.msard.2019.01.042 · 2019 · External reference
10.1214/09-sts301
10.1214/09-sts301 · External reference
Calculating and comparing the annualized relapse rate and estimating the confidence interval in relapsing neurological diseases
10.3389/fneur.2022.875456 · 2022 · External reference
Bayesian augmented clinical trials in TB therapeutic vaccination
10.3389/fmedt.2021.719380 · 2021 · External reference
Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate
10.1007/s00415-019-09557-w · 2020 · External reference
Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI
10.1212/wnl.52.3.588 · 1999 · External reference
Pathology and disease mechanisms in different stages of multiple sclerosis
10.1016/j.jns.2013.05.010 · 2013 · External reference
Novel immunomodulatory approaches for the management of multiple sclerosis
10.1038/clpt.2013.196 · 2014 · External reference
Cladribine tablets: a review in relapsing MS
10.1007/s40263-018-0562-0 · 2018 · External reference
